487 related articles for article (PubMed ID: 24713296)
1. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
[TBL] [Abstract][Full Text] [Related]
2. Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.
Tsunetoh S; Terai Y; Sasaki H; Tanabe A; Tanaka Y; Sekijima T; Fujioka S; Kawaguchi H; Kanemura M; Yamashita Y; Ohmichi M
Cancer Biol Ther; 2010 Dec; 10(11):1137-46. PubMed ID: 20935474
[TBL] [Abstract][Full Text] [Related]
3. Theasaponin E
Li B; Tong T; Ren N; Rankin GO; Rojanasakul Y; Tu Y; Chen YC
Molecules; 2021 Mar; 26(6):. PubMed ID: 33802884
[TBL] [Abstract][Full Text] [Related]
4. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
6. Activation of estrogen receptor α by estradiol and cisplatin induces platinum-resistance in ovarian cancer cells.
Matsumura S; Ohta T; Yamanouchi K; Liu Z; Sudo T; Kojimahara T; Seino M; Narumi M; Tsutsumi S; Takahashi T; Takahashi K; Kurachi H; Nagase S
Cancer Biol Ther; 2017 Sep; 18(9):730-739. PubMed ID: 27689466
[TBL] [Abstract][Full Text] [Related]
7. Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway.
Wang P; Hu Y; Qu P; Zhao Y; Liu J; Zhao J; Kong B
Bioengineered; 2022 Jan; 13(1):1931-1941. PubMed ID: 35001804
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma.
Rose PG
Int J Gynecol Cancer; 2005; 15 Suppl 1():18-22. PubMed ID: 15839954
[TBL] [Abstract][Full Text] [Related]
9. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro.
Hahne JC; Honig A; Meyer SR; Gambaryan S; Walter U; Wischhusen J; Häussler SF; Segerer SE; Fujita N; Dietl J; Engel JB
Oncol Rep; 2012 Dec; 28(6):2023-8. PubMed ID: 22992944
[TBL] [Abstract][Full Text] [Related]
11. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
Subramaniam D; Periyasamy G; Ponnurangam S; Chakrabarti D; Sugumar A; Padigaru M; Weir SJ; Balakrishnan A; Sharma S; Anant S
Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
[TBL] [Abstract][Full Text] [Related]
12. Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity.
Treviño JG; Verma M; Singh S; Pillai S; Zhang D; Pernazza D; Sebti SM; Lawrence NJ; Centeno BA; Chellappan SP
Mol Cancer Ther; 2013 Dec; 12(12):2722-34. PubMed ID: 24107447
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models.
Mabuchi S; Ohmichi M; Nishio Y; Hayasaka T; Kimura A; Ohta T; Saito M; Kawagoe J; Takahashi K; Yada-Hashimoto N; Sakata M; Motoyama T; Kurachi H; Tasaka K; Murata Y
J Biol Chem; 2004 May; 279(22):23477-85. PubMed ID: 15026414
[TBL] [Abstract][Full Text] [Related]
14. BLU enhances the effects of anti-angiogenic activity in combination with gemcitabine-based chemotherapeutic agents.
Yoo HJ; Kim BR; Byun HJ; Park SY; Rho SB
Int J Biochem Cell Biol; 2013 Jul; 45(7):1236-45. PubMed ID: 23579097
[TBL] [Abstract][Full Text] [Related]
15. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
16. Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway.
Wu ZH; Lin C; Liu MM; Zhang J; Tao ZH; Hu XC
PLoS One; 2016; 11(12):e0169230. PubMed ID: 28036386
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
Sasano T; Mabuchi S; Kuroda H; Kawano M; Matsumoto Y; Takahashi R; Hisamatsu T; Sawada K; Hashimoto K; Isobe A; Testa JR; Kimura T
Mol Cancer Res; 2015 Apr; 13(4):795-806. PubMed ID: 25519148
[TBL] [Abstract][Full Text] [Related]
18. Restoration of microRNA-708 sensitizes ovarian cancer cells to cisplatin via IGF2BP1/Akt pathway.
Qin X; Sun L; Wang J
Cell Biol Int; 2017 Oct; 41(10):1110-1118. PubMed ID: 28685895
[TBL] [Abstract][Full Text] [Related]
19. Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study.
Brandi G; Tavolari S; Guarnieri T; Di Marco M; Paterini P; Macchini M; Di Girolamo S; Papi A; De Rosa F; Biasco G
Pancreas; 2014 Jan; 43(1):53-63. PubMed ID: 24201777
[TBL] [Abstract][Full Text] [Related]
20. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]